缓解医疗器械行业风险与干扰：艾昆纬加拿大对贸易不确定性的应对策略

Mitigating Risk and Disruptionin the MedTech Sector An IQVIA MedTech Canada perspective on navigatingthe trade uncertainties DHEEMAN VAIDYA, Director, Business Development, IQVIA MedTechANASTASIA CHERNYATINA, Senior Consultant, IQVIA MedTech Table of contents Executive summary1Potential impact of new tariffs on MedTech1Canada: Impacts on various device categories3Canada and the United States: Impact on MedTech manufacturers5Canada: Resilience in the MedTech market6Canada: Insights for navigating disruptive MedTech market change6Short- to medium-term strategies6Medium- to long-term strategies9Conclusion9IQVIA MedTech provides a data-driven methodology to assist companiesin managing uncertainty effectively10References12About the authors14 Potential impact of newtariffs on MedTech Executive summary The MedTech sector is currently facing a period ofongoing risk and disruption. Recent challenges haveincluded the global semiconductor shortage andother supply chain issues triggered by the COVID-19pandemic, as well as events in the Gulf and Ukraine.Most recently, trade issues have arisen due to swiftU.S. trade policy changes and the imposition of tariffson goods from Canada, Mexico, and China. Thesetariffs, along with potential retaliatory measures, posea risk to the MedTech sector due to its complex supplychain, which relies heavily on offshore manufacturing.1The result is likely to be increased costs for medicaldevices, negatively affecting healthcare and reducingsales outside of the U.S.2 As of the time of writing, the Trump administration hasimposed a 25% additional tariff on imports from Canadaand Mexico. On April 2nd, U.S. “Liberation Day” introducedhigh tariffs globally, with the U.S. implementing a 10%baseline tariff on all countries. Customized higher tariffrates are being applied to 60 countries where the U.S.has significant trade deficits. This includes cumulativeadditional tariffs on imports from China, now totalingan additional tax of104%. For European Union imports,the tariff stands at 20%, and 25% on steel andaluminum. In response, countries including CanadaandChinahave retaliated with tariffs on U.S.imports,creating increased uncertainty across global marketsas the situation continues to unfold. Authored by IQVIA MedTech experts, this paperexplores the potential impact of tariffs on theCanadian MedTech market and outlines strategiesfor manufacturers to consider. Key steps includeundertaking scenario and sensitivity analyses, as wellas formulating strategic plans with market insightsand competitive intelligence. While Canada is usedas a case study, the recommendations apply equallyto MedTech companies in other regions. The authorspropose a range of short- and long-term strategies tohelp companies build competitive advantages as theynavigate the rapidly evolving global MedTech landscape. In light of the potential for negative impacts on thesector, Medtech Canada, Canada’s MedTech industryassociation, is advocating for the exclusion of medicaldevices from any retaliatory tariffs or sanctions, citinglikely impacts on health care systems and patients.4U.S. trade groups such as AdvaMed5and the AmericanHospital Association6are also opposing the tariffs,arguing that tariffs could harm innovation, disrupt supplychains, and lead to shortages, ultimately negativelyaffecting patients. AdvaMed has been pushing fora MedTech carve-out from the tariffs, similar to the exemption given to this sector when tariffs on Chinawere imposed during President Trump’s first term.7 THE MEDTECH LANDSCAPE IN CANADA Historically, Canadian medical technologies have hadtariff-free access to the U.S. market, with no tariffs onMedTech goods exported from the U.S. to Canada. Newtariffs, both from the U.S. and from Canada in retaliation,are expected to impact the competitiveness of companiestrading across the U.S.-Canadian border. Tariffs on U.S.imports are also significant because the industry relieson raw materials from China and subassembly workin Mexico, Canada and the EU.While increased costsfrom tariffs could eventually be passed on to healthcaresystems and patients, companies would likely first seekdomestic suppliers or consider geographic reallocationof production, sourcing and procurement. Canada’s medical devices market was valuedat US$9.47billion in 2022, excluding in vitrodiagnostics; this accounted for 2.3% of theglobal market.MedTech Canada estimatesthat Canada’s medical device industryis the world’s 8th largest, with more than1,500 medical technology companies.These are primarily located in the threelargest provinces, Ontario, Quebec andBritish Columbia.10 The value of medical device imports from theU.S. reached US$4 billion in 2022, accountingfor 38% of total medical device imports intoCanada; other sources of device importswere China (17%), Mexico (7%), and Germany(5%)(Figure 1).11In 2022 Canada’s medicaldevice exports to the U.S. amounted toCAD$2.4 billion, which represented 74%of the country’s total med